HGH Fragment 176-191 (5mg)

HGH Fragment 176-191 (5mg) protocols focus on this modified segment of human growth hormone, studied for its potential role in supporting fat metabolism and lipolysis without the full systemic effects of HGH. This fragment is believed to target adipose tissue specifically, promoting fat breakdown while minimizing impact on blood sugar or growth pathways. This guide outlines a subcutaneous administration approach optimized for the 5 mg vial format.

  • Reconstitute: Add 1.0 mL bacteriostatic water → 5 mg/mL concentration
  • Typical daily range: 250–500 mcg once or twice daily (subcutaneous)
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks

Concise summary of the subcutaneous regimen.

  • Goal: Support fat loss via targeted lipolysis mechanisms
  • Schedule: Daily subcutaneous injections, often split AM/PM
  • Dose Range: 250–500 mcg per dose

Suggested approach for the 5 mg vial format.

  • Start: 250 mcg once daily to assess tolerance
  • Target: 250–500 mcg once or twice daily
  • Frequency: 1–2 times per day (subcutaneous)
  • Vial Duration: One 5 mg vial lasts approximately 5–20 days, depending on dose
  • Timing: Best taken on an empty stomach or between meals for metabolic focus

HGH Fragment 176-191 is a modified portion of the human growth hormone molecule, engineered to isolate its lipolytic (fat-burning) properties while removing effects associated with growth, insulin resistance, or IGF-1 elevation.

It is believed to act directly on adipose tissue by enhancing fat breakdown (lipolysis) and inhibiting fat storage. Research suggests it may increase the activity of hormone-sensitive lipase, an enzyme responsible for mobilizing stored fat for energy use. Unlike full HGH, this fragment does not appear to significantly affect blood glucose, IGF-1 levels, or tissue growth pathways in preclinical studies.

Observations based on preclinical and early-stage research.

Potential Benefits:

  • May support the reduction of body fat, especially abdominal fat
  • May enhance lipolysis without affecting IGF-1 pathways
  • May support improved body composition when combined with diet and exercise
  • Does not appear to promote unwanted tissue growth effects associated with HGH

Possible Side Effects:

  • Mild injection-site irritation
  • Temporary flushing or headache in some cases
  • Limited human clinical data; long-term safety not fully established
  • Remains an investigational research compound